Wild-type (senile) amyloidosis laboratory findings: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Wild-type (senile) amyloidosis}} {{CMG}} ==Overview== ==Laboratory Findings== ==References== {{Reflist|2}} Category:Disease Category:Cardiology Categ...") |
No edit summary |
||
| Line 6: | Line 6: | ||
==Laboratory Findings== | ==Laboratory Findings== | ||
* Wild-type (senile) amyloidosis is a diagnosis of exclusion. | |||
* Laboratory tests are conducted to evaluate for the presence or absence AL amyloid protein deposition. | |||
* The absence of AL amyloid provides a strong clue towards the diagnosis of wild-type (senile) amyloidosis. | |||
==='''Cardiac'''=== | |||
*[[Cardiac biomarkers]] are the most important predictors of outcome in amyloidosis. | |||
*They provide a quantitative assessment for [[Heart|cardiac]] damage and wall strain.<ref name="pmid21483018">{{cite journal |vauthors=Merlini G, Seldin DC, Gertz MA |title=Amyloidosis: pathogenesis and new therapeutic options |journal=J. Clin. Oncol. |volume=29 |issue=14 |pages=1924–33 |date=May 2011 |pmid=21483018 |pmc=3138545 |doi=10.1200/JCO.2010.32.2271 |url=}}</ref> | |||
*The [[biomarkers]] include: | |||
:*[[Troponin I]] or [[Troponin T]] | |||
:*BNP and NT-proBNP | |||
==References== | ==References== | ||
Revision as of 21:29, 17 December 2019
|
Wild-type (senile) amyloidosis Microchapters |
|
Differentiating Wild-type (senile) amyloidosis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Wild-type (senile) amyloidosis laboratory findings On the Web |
|
American Roentgen Ray Society Images of Wild-type (senile) amyloidosis laboratory findings |
|
Wild-type (senile) amyloidosis laboratory findings in the news |
|
Risk calculators and risk factors for Wild-type (senile) amyloidosis laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Laboratory Findings
- Wild-type (senile) amyloidosis is a diagnosis of exclusion.
- Laboratory tests are conducted to evaluate for the presence or absence AL amyloid protein deposition.
- The absence of AL amyloid provides a strong clue towards the diagnosis of wild-type (senile) amyloidosis.
Cardiac
- Cardiac biomarkers are the most important predictors of outcome in amyloidosis.
- They provide a quantitative assessment for cardiac damage and wall strain.[1]
- The biomarkers include:
- Troponin I or Troponin T
- BNP and NT-proBNP
References
- ↑ Merlini G, Seldin DC, Gertz MA (May 2011). "Amyloidosis: pathogenesis and new therapeutic options". J. Clin. Oncol. 29 (14): 1924–33. doi:10.1200/JCO.2010.32.2271. PMC 3138545. PMID 21483018.